To support the growth of its members on specific aspects relating to their development, BioWin wishes to cooperate more proactively with its “associate” members, service companies whose quality and expertise are recognized and which provide real added value to the entire ecosystem.
The partnership approach will enable BioWin to organize events featuring themes that are relevant to the concerns of the cluster’s members.
“We are delighted to have concluded this agreement with Ayming, a consultancy firm specialized in improving business performance.” said Sylvie Ponchaut, Managing Director of BioWin. “We wish to accelerate the growth of our businesses by means of even more targeted contacts through these novel partnerships with our association members.”
Thanks to its up-to-the-minute knowledge of the funding requirements for the scientific activities of biotech companies, Ayming Belgium has emerged as an asset of choice for BioWin and its members, as a driver of growth and expert advisor in defining, implementing and managing the financing strategy of their innovations – a process which starts with a scientific audit carried out through a financial lens and which then goes on to mapping the structure of the organization and its activities in order to identify potential eligibility.
Ayming Belgium places services at the disposal of the BioWin ecosystem to accelerate and anticipate the development of an organization by identifying all the public funding available in the administrative jungle, and then proceeding to implement it in a concrete, operational and secure manner on behalf of companies that might not benefit from them otherwise, lacking the required knowledge or expertise.
Laurie Pilo, Managing Director of Ayming Benelux, added: “This cooperation with BioWin is a natural development: the combination of our expertise in innovation and our references in biotech enables us to provide real added value to the members of BioWin, who face difficulties we are familiar with. More specifically, according to our market studies, although 8 out of 10 companies consider the optimization of financial resources dedicated to R&D as a priority, they deem themselves moderately mature when it comes to mastering funding for their innovation. We can provide this expertise, and we are delighted to help to promote Belgian excellence in biotechnologies.”